The Global Health Body Issues Alert Over Severe Shortage of Weight-Loss Jabs

Under a tenth of people who could benefit from obesity jabs including Wegovy are able to get them, states the global health agency as it releases its inaugural advice on the therapies.

Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.

Based on estimates, over two billion could be obese by 2030 without intervention.

"Our latest guidance recognises that obesity is a long-term condition that can be treated with holistic and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are significant obstacles to broad availability to the jabs that can assist patients in reducing considerable weight, notes the agency.

Skinny Jab Shortage

Even under the present best projected outlook, the manufacturing of these medications could only cover around 100 million people – less than 10% of those who need them, per the health organization.

The guideline calls on governments and firms to widen access, by measures including voluntary licensing.

Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in multiple countries in 2026.

The Way Obesity Injections Work

GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals consume fewer calories.

People typically see weight reduction within a few weeks of beginning the once-weekly jabs.

Evidence indicates users may put most of the weight back on after a year of discontinuing the drug, as their normal appetite come back.

Being above a healthy weight increases your risk for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.

Obesity impacts people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.